Immune globulin 5% - Octapharma

Drug Profile

Immune globulin 5% - Octapharma

Alternative Names: octagam; Octagam; Octagam 5%; Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Octapharma
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders
  • Phase III Multiple sclerosis

Most Recent Events

  • 18 Dec 2013 Phase-III clinical trials in Multiple sclerosis in Bulgaria (IV)
  • 31 May 2013 Octapharma initiates enrolment in a postmarketing trial for Immunodeficiency disorders in USA (NCT01859754)
  • 09 May 2013 Re-launched for Immunodeficiency disorders in Belgium before May 2013 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top